Live symbol workspace

PFE market intelligence

Chart, AI analysis, key levels, technical analysis, sentiment, and market news are grouped so the next action is always visible.

Current $28.32

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$26.90

Resistance

$29.74

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Analysis

HOLD

Entry $28.32

Stop $26.90

Target $29.74

RSI: 50 | Current: $28.32

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

— 0.0 pts vs previous week

Avg confidence across 16 calls in the last 7 days

What sources say

No news-sourced AI calls in the last 30 days.

Insider Trading

Refreshing insider trades from FinViz…

Technical Signals

Refreshing technical signals from FinViz…

PFE News Intelligence (7 articles)

AI-curated news influencing PFE price, sentiment, and trend

Explore All PFE News with AI Analysis

Economy

1 month, 1 week ago

Better Buy Right Now: Johnson & Johnson Vs. Pfizer

The choice is based on more than just the dividend payout.

Impact on PFE: Insufficient data to determine direct market consequences, but a positive or negative …

The article compares Johnson & Johnson and Pfizer as investment options, considering factors beyond dividend … Low (20%)

View full analysis →

Yahoo Finance 20% confidence

Economy

1 month, 1 week ago

Japan to Work With Asian Nations to Ease Oil Bottleneck: Akazawa

Japan will work closely with Asian countries where essential petroleum-based products including medical equipment are produced, economy minister Ryosei Akazawa …

Impact on PFE: The news may lead to a decrease in oil prices and a …

Japan's economy minister announced plans to collaborate with Asian nations to alleviate oil supply chain … High (70%)

View full analysis →

Bloomberg 70% confidence

Economy

1 month, 2 weeks ago

2 Reasons to Watch PFE and 1 to Stay Cautious

Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have …

Impact on PFE: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Stocks

1 month, 2 weeks ago

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy …

Impact on PFE: Soleno Therapeutics' stock is soaring in premarket trading, with potential for a …

Neurocrine's potential acquisition of Soleno Therapeutics is driving a surge in Soleno's stock price, with … High (80%)

View full analysis →

MarketWatch 80% confidence

Economy

2 months ago

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Impact on PFE: AbbVie's (ABBV) undervaluation could lead to a price increase, potentially driving the …

AbbVie's strong financials, attractive dividend, and modest valuation make its stock appear undervalued, presenting a … High (70%)

View full analysis →

Yahoo Finance 70% confidence

Stocks

2 months ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on PFE: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence